- Partnership will explore new healthcare opportunities arising from the link between sleep disorders and cardiovascular disease
- Collaboration to span the integration of sleep data with cardiovascular risk factors, academic initiatives, and more
- Philips’ health technology expertise and HoneyNaps’ FDA-authorized AI capabilities aim to help shape the next generation of healthcare
BOSTON, Aug. 28, 2026 /PRNewswire/ — As sleep health increasingly emerges as an important factor in the prevention and management of cardiovascular disease, the medical community is paying greater attention to the relationship between sleep disorders and cardiovascular conditions
Major sleep disorders, particularly obstructive sleep apnea, have been consistently associated with a range of cardiovascular conditions, including hypertension, atrial fibrillation, heart failure, coronary artery disease, and stroke. These findings underscore the need for a more integrated approach that incorporates sleep health into cardiovascular risk assessment and disease management
Against this backdrop, health technology company Philips Korea and AI-powered sleep medicine company HoneyNaps announced that they signed a memorandum of understanding (MOU) on August 19 to establish a strategic partnership and explore new healthcare opportunities at the intersection of sleep and cardiovascular health
Under the agreement, the two companies will jointly identify new medical and healthcare business opportunities by examining the relationship between sleep and cardiovascular health. They will also explore potential expansion into cardiology and other cardiovascular disease-related areas
Philips is a leading health technology company committed to improving people’s health and well-being through meaningful innovation. Guided by a patient- and consumer-centric approach, the company leverages advanced technology as well as clinical and consumer insights to provide healthcare solutions for professionals, patients, and consumers across hospital and home settings
Philips’ Sleep and Respiratory Care business provides solutions for the management and treatment of sleep and respiratory disorders, including sleep apnea, supporting healthcare professionals and patients in the continuous management of health
HoneyNaps is an AI-powered sleep medicine company that provides solutions for the diagnosis and analysis of sleep disorders based on AI technology authorized by the U.S. Food and Drug Administration. The company has developed an end-to-end sleep healthcare platform encompassing biosignal sensing, analysis, diagnosis, and treatment. It has also recently expanded into the contract research organization (CRO) business as part of its broader entry into the clinical trials market.
“This agreement is significant because it brings together the expertise and commercial capabilities of both companies to explore new healthcare opportunities based on the relationship between sleep and cardiovascular health,” said Sean Ha (Tae Kyoung Ha), President of HoneyNaps USA
“Going forward, we will actively explore ways to integrate sleep data with cardiovascular risk factors in cardiology and cardiovascular disease care. We also plan to broaden our collaboration through academic initiatives and other activities, creating new value that encompasses both sleep and cardiovascular health.”
For further information, please contact:
HoneyNaps USA, Inc.Christine Kwon / Managing DirectorEmail: [email protected]Address: 14th Floor, One Broadway, Cambridge, MA 02142, USAWebsite: www.honeynaps.com
SOURCE HoneyNaps
